Preclinical Pharmacodynamic Evaluation of Cardiovascular Drugs

Pharmacodynamic evaluation is one of the core aspects for cardiovascular drug development. Ace Therapeutics strives to advance drug discovery and development for cardiovascular disease by providing preclinical pharmacodynamic study services to clients.

Pharmacodynamic Study Method of Cardiovascular Drugs

Preclinical pharmacodynamic studies are an important stage in the development of new cardiovascular drugs, and commonly used research methods include in vitro and in vivo studies. Studies at the in vitro level focus on the drug's effect on specific cell types, inhibition or activation of specific enzymes, and affinity and selectivity for drug targets and receptors. In vivo studies, on the other hand, evaluate the pharmacodynamic profile of drugs on common experimental animal models. In addition to this, in recent years, with the rapid development of theories and methods of some new technologies, such as Quantitative Systems Pharmacology (QSP), Machine Learning (ML), Artificial Intelligence (AI)-based (AI)-based pharmacodynamic research methods have also been gradually applied to the pharmacodynamic study of cardiovascular diseases.

Fig. 1 Cardioprotective actions of Finerenone. (Kintscher U, and Edelmann F, 2023)

Ace Therapeutics can provide clients with preclinical pharmacodynamic study services to support the development of drugs for cardiovascular diseases.

Ace Therapeutics is a contract research organization specializing in drug research for cardiovascular diseases. With our specialized equipment platform and dedicated research team, we can provide comprehensive solutions for preclinical pharmacodynamic studies of cardiovascular drugs. If you are interested in our services, please don't hesitate to contact us.

1. Kintscher, U.; Edelmann, F. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2023, 22(1):162.